Gene study aims to personalize blood thinner dosing

NCT ID NCT00162474

Recruiting now Knowledge-focused Sponsor: Hadassah Medical Organization Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how genetic differences in the CYP2C9 enzyme affect the way healthy volunteers process warfarin and similar drugs. Researchers will give participants single doses of one or more of these drugs and measure how their bodies break them down. The goal is to better understand why people respond differently to these medications, which could lead to safer, more personalized dosing in the future.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Warfarin, Phenytoin, Losartan, Flurbiprofen, Siponimod
What this could lead to: If successful, this could help doctors predict the right dose of warfarin and similar drugs based on a person's genes, reducing side effects.
What could go wrong: This is an early-stage observational study in healthy people, not patients. The findings may not directly change clinical practice and need further validation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY

Contacts and locations

Locations

Hadassah Medical Organization
RECRUITING

Jerusalem, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.